Increased all-cause and cancer mortality in HTLV-II infection

Journal of Acquired Immune Deficiency Syndromes

Volumn 54, Issue 3, 2010, Pages 290-296

  Biswas, Hope H ^a   Kaidarova, Zhanna ^a   Garratty, George ^b   Gibble, Joan W ^b   Newman, Bruce H ^b   Smith, James W ^c   Ziman, Alyssa ^d   Fridey, Joy L ^e   Sacher, Ronald A ^f   Murphy, Edward L ^a,g  

^a BLOOD SYSTEMS RESEARCH INSTITUTE   (United States)

^b AMERICAN RED CROSS BLOOD SERVICES   (United States)

^c Oklahoma Blood Institute   (United States)

^d UCLA MEDICAL CENTER   (United States)

^e CHILDREN S HOSPITAL LOS ANGELES   (United States)

^f UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^g UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER MORTALITY; CAUSE OF DEATH; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; HUMAN; HUMAN T CELL LEUKEMIA VIRUS 1; HUMAN T CELL LEUKEMIA VIRUS 2; HUMAN T CELL LEUKEMIA VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CAUSE OF DEATH; FEMALE; HTLV-II INFECTIONS; HUMAN T-LYMPHOTROPIC VIRUS 2; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; UNITED STATES; YOUNG ADULT;

EID: 77954084531     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAI.0b013e3181cc5481     Document Type: Article

References (27)

1. Etenna SL, Caron M, Besson G, et al. New insights into prevalence, genetic diversity, and proviral load of human T-cell leukemia virus types 1 and 2 in pregnant women in Gabon in equatorial central Africa. J Clin Microbiol. 2008;46:3607-3614.
2. Iwanaga M, Chiyoda S, Kusaba E, et al. Trends in the seroprevalence of HTLV-1 in Japanese blood donors in Nagasaki Prefecture, 2000-2006. Int J Hematol. 2009;23:23.
3. Gotuzzo E, Terashima A, Alvarez H, et al. Strongyloides stercoralis hyperinfection associated with human T cell lymphotropic virus type-1 infection in Peru. Am J Trop Med Hyg. 1999;60:146-149.
4. Feuer G, Green PL. Comparative biology of human T-cell lymphotropic virus type 1 (HTLV-1) and HTLV-2. Oncogene. 2005;24:5996-6004.
5. Orland JR, Engstrom J, Fridey J, et al. Prevalence and clinical features of HTLV neurologic disease in the HTLV Outcomes Study. Neurology. 2003; 61:1588-1594.
6. Murphy EL, Wang B, Sacher RA, et al. Respiratory and urinary tract infections, arthritis, and asthma associated with HTLV-I and HTLV-II infection. Emerg Infect Dis. 2004;10:109-116.
7. Holmgren B, da Silva Z, Vastrup P, et al. Mortality associated with HIV-1, HIV-2, and HTLV-I single and dual infections in a middle-aged and older population in Guinea-Bissau. Retrovirology. 2007;4:85.
8. Arisawa K, Sobue T, Yoshimi I, et al. Human T-lymphotropic virus type-I infection, survival and cancer risk in southwestern Japan: a prospective cohort study. Cancer Causes Control. 2003;14:889-896.
9. Arisawa K, Soda M, Akahoshi M, et al. Human T-lymphotropic virus type-I infection, antibody titers and cause-specific mortality among atomic-bomb survivors. Jpn J Cancer Res. 1998;89:797-805.
10. Lechat MF, Shrager DI, Declercq E, et al. Decreased survival of HTLV-I carriers in leprosy patients from the Democratic Republic of the Congo: a historical prospective study. J Acquir Immune Defic Syndr Hum Retrovirol. 1997;15:387-390.
11. Orland JR, Wang B, Wright DJ, et al. Increased mortality associated with HTLV-II infection in blood donors: a prospective cohort study. Retrovirology. 2004;1:4.
12. Goedert JJ, Fung MW, Felton S, et al. Cause-specific mortality associated with HIV and HTLV-II infections among injecting drug users in the USA. AIDS. 2001;15:1295-1302.
13. Hershow RC, Galai N, Fukuda K, et al. An international collaborative study of the effects of coinfection with human T-lymphotropic virus type II on human immunodeficiency virus type 1 disease progression in injection drug users. J Infect Dis. 1996;174:309-317.
14. Visconti A, Visconti L, Bellocco R, et al. HTLV-II/HIV-1 coinfection and risk for progression to AIDS among intravenous drug users. J Acquir Immune Defic Syndr. 1993;6:1228-1237.
15. Giacomo M, Franco EG, Claudio C, et al. Human T-cell leukemia virus type II infection among high risk groups and its influence on HIV-1 disease progression. Eur J Epidemiol. 1995;11:527-533.
16. Murphy EL, Glynn SA, Fridey J, et al. Increased prevalence of infectious diseases and other adverse outcomes in human T lymphotropic virus types I-and II-infected blood donors. Retrovirus Epidemiology Donor Study (REDS) Study Group. J Infect Dis. 1997; 176:1468-1475.
17. Patel P, Hanson DL, Sullivan PS, et al. Incidence of types of cancer among HIV-infected persons compared with the general population in the United States, 1992-2003. Ann Intern Med. 2008;148:728-736.
18. Dal Maso L, Serraino D, Franceschi S. Epidemiology of AIDS-related tumours in developed and developing countries. Eur J Cancer. 2001;37: 1188-1201.
19. Bouvard V, Baan R, Straif K, et al. A reviewof human carcinogens-Part B: biological agents. Lancet Oncol. 2009;10:321-322.
20. Hirata T, Uchima N, Kishimoto K, et al. Impairment of host immune response against strongyloides stercoralis by human T cell lymphotropic virus type 1 infection. Am J Trop Med Hyg. 2006;74:246-249.
21. Mascarenhas RE, Brodskyn C, Barbosa G, et al. Peripheral blood mononuclear cells from individuals infected with human T-cell lymphotropic virus type 1 have a reduced capacity to respond to recall antigens. Clin Vaccine Immunol. 2006;13:547-552.
22. Bartman MT, Kaidarova Z, Hirschkorn D, et al. Long-term increases in lymphocytes and platelets in human T-lymphotropic virus type II infection. Blood. 2008;112:3995-4002.
23. Prince H, Kleinman S, Doyle M, et al. Spontaneous lymphocyte proliferation in vitro characterizes both HTLV-I and HTLV-II infection. J Acquir Immune Defic Syndr. 1990;3:1199-1200.
24. Boschi-Pinto C, Stuver S, Okayama A, et al. A follow-up study of morbidity and mortality associated with hepatitis C virus infection and its interaction with human T lymphotropic virus type I in Miyazaki, Japan. J Infect Dis. 2000;181:35-41.
25. Bangham CR. The immune control and cell-to-cell spread of human T-lymphotropic virus type 1. J Gen Virol. 2003;84:3177-3189.
26. Frishman WH, Ismail AA. Role of infection in atherosclerosis and coronary artery disease: a new therapeutic target? Cardiol Rev. 2002;10: 199-210.
27. Norris PJ, Hirschkorn DF, DeVita DA, et al. Human T-cell leukemia virus type 1 infection drives spontaneous proliferation of natural killer cells. Virulence (in press).